Galmed Pharmaceuticals Ltd.
Every calculator, already run for GLMD
Open the full toolkit →You have the numbers on GLMD. Get the argument.
A written report on which of these readings actually decide the outcome for Galmed Pharmaceuticals Ltd., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
1 analysts covering GLMDOwnership & short interest
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methi…
GLMD — frequently asked
Is GLMD a buy right now?
Wall Street's consensus rating on Galmed Pharmaceuticals Ltd. is none across 1 analysts. Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Compare Galmed Pharmaceuticals Ltd. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Galmed Pharmaceuticals Ltd.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full GLMD research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Galmed Pharmaceuticals Ltd., in minutes. 3 free reports included with every account — no credit card required.